Q3-osavuosiraportti
TänäänÄänite tulossa
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
67
Myynti
Määrä
3 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 | NON | NON | ||
| 50 | NON | NON | ||
| 200 | NON | SSWM | ||
| 2 000 | NON | NON | ||
| 50 | NON | NON |
Ylin
6,3VWAP
Alin
5,56VaihtoMäärä
0,8 133 292
VWAP
Ylin
6,3Alin
5,56VaihtoMäärä
0,8 133 292
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 321 | 330 | +20 991 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 231 | 22 085 | −19 854 | 961 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sittenCurasight: Timeline for significant readouts confirmed today at 12:14 ∙ Inderes Curasight -6.15% Curasight presented its Q3 2025 report this morning. The third quarter brought several significant milestones that advanced the pipeline. The company also confirms the timeline for upcoming significant data. Curasight: Timeline for significant readouts confirmed
·13 t sitten · MuokattuSo the Q3 report is out, I see it this way. Overall, the report looks typical for an early-stage biotech company in a growth phase. Higher losses, but increased liquidity and clinical progress that could potentially attract partners or investors. Liquidity has doubled to 15.9 million, which is very positive. So we are heading into very exciting times. The CEO also sounds very optimistic and highlights significant clinical and strategic progress. Which I personally see as a very good thing. Have a great day everyone.
1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·21 t sitten · MuokattuBut there just came a First Trial news late in the afternoon, that is exciting and could give a bit more interest. It looks like they are starting up with the first patient with brain cancer within a few weeks. I have great hopes, for the patients first and foremost, but also a little for us others :)
1 päivä sitten1 päivä sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
TänäänÄänite tulossa
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenCurasight: Timeline for significant readouts confirmed today at 12:14 ∙ Inderes Curasight -6.15% Curasight presented its Q3 2025 report this morning. The third quarter brought several significant milestones that advanced the pipeline. The company also confirms the timeline for upcoming significant data. Curasight: Timeline for significant readouts confirmed
- ·13 t sitten · MuokattuSo the Q3 report is out, I see it this way. Overall, the report looks typical for an early-stage biotech company in a growth phase. Higher losses, but increased liquidity and clinical progress that could potentially attract partners or investors. Liquidity has doubled to 15.9 million, which is very positive. So we are heading into very exciting times. The CEO also sounds very optimistic and highlights significant clinical and strategic progress. Which I personally see as a very good thing. Have a great day everyone.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·21 t sitten · MuokattuBut there just came a First Trial news late in the afternoon, that is exciting and could give a bit more interest. It looks like they are starting up with the first patient with brain cancer within a few weeks. I have great hopes, for the patients first and foremost, but also a little for us others :)
- 1 päivä sitten1 päivä sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
67
Myynti
Määrä
3 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 | NON | NON | ||
| 50 | NON | NON | ||
| 200 | NON | SSWM | ||
| 2 000 | NON | NON | ||
| 50 | NON | NON |
Ylin
6,3VWAP
Alin
5,56VaihtoMäärä
0,8 133 292
VWAP
Ylin
6,3Alin
5,56VaihtoMäärä
0,8 133 292
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 321 | 330 | +20 991 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 231 | 22 085 | −19 854 | 961 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
TänäänÄänite tulossa
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenCurasight: Timeline for significant readouts confirmed today at 12:14 ∙ Inderes Curasight -6.15% Curasight presented its Q3 2025 report this morning. The third quarter brought several significant milestones that advanced the pipeline. The company also confirms the timeline for upcoming significant data. Curasight: Timeline for significant readouts confirmed
- ·13 t sitten · MuokattuSo the Q3 report is out, I see it this way. Overall, the report looks typical for an early-stage biotech company in a growth phase. Higher losses, but increased liquidity and clinical progress that could potentially attract partners or investors. Liquidity has doubled to 15.9 million, which is very positive. So we are heading into very exciting times. The CEO also sounds very optimistic and highlights significant clinical and strategic progress. Which I personally see as a very good thing. Have a great day everyone.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·21 t sitten · MuokattuBut there just came a First Trial news late in the afternoon, that is exciting and could give a bit more interest. It looks like they are starting up with the first patient with brain cancer within a few weeks. I have great hopes, for the patients first and foremost, but also a little for us others :)
- 1 päivä sitten1 päivä sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
67
Myynti
Määrä
3 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 | NON | NON | ||
| 50 | NON | NON | ||
| 200 | NON | SSWM | ||
| 2 000 | NON | NON | ||
| 50 | NON | NON |
Ylin
6,3VWAP
Alin
5,56VaihtoMäärä
0,8 133 292
VWAP
Ylin
6,3Alin
5,56VaihtoMäärä
0,8 133 292
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 321 | 330 | +20 991 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 231 | 22 085 | −19 854 | 961 |
| Nordnet Bank AB | 82 071 | 99 536 | −17 465 | 70 204 |
| Swedbank AB | 0 | 463 | −463 | 0 |
| Svenska Handelsbanken AB | 400 | 0 | +400 | 0 |
| Danske Bank A/S | 4 317 | 0 | +4 317 | 0 |
| SSW Market Making GmbH | 22 952 | 10 878 | +12 074 | 0 |